Works matching AU Zhou, Keshu

Results: 37
    1
    2
    3

    Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study.

    Published in:
    Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01646-2
    By:
    • Yang, Jianliang;
    • Song, Yongping;
    • Zhou, Keshu;
    • Li, Zhiming;
    • Zhang, Mingzhi;
    • Jing, Hongmei;
    • Wang, Zhen;
    • Yu, Li;
    • Meng, Wei;
    • Lu, Qiying;
    • Tian, Wenzhi;
    • Shi, Yuankai
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.

    Published in:
    Annals of Hematology, 2024, v. 103, n. 10, p. 4183, doi. 10.1007/s00277-024-05823-8
    By:
    • Zhou, Keshu;
    • Wang, Tingyu;
    • Pan, Ling;
    • Xu, Wei;
    • Jin, Jie;
    • Zhang, Wei;
    • Hu, Yu;
    • Hu, Jianda;
    • Feng, Ru;
    • Li, Ping;
    • Liu, Zhougang;
    • Liu, Peng;
    • Jing, Hongmei;
    • Gao, Sujun;
    • Zhang, Huilai;
    • Yu, Kang;
    • Wang, Zhao;
    • Zhu, Xiongpeng;
    • Sun, Zimin;
    • Li, Fei
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16

    Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 18, p. 18643, doi. 10.1002/cam4.6473
    By:
    • Song, Yuqin;
    • Zhou, Keshu;
    • Zou, Dehui;
    • Li, Dengju;
    • Hu, Jianda;
    • Yang, Haiyan;
    • Zhang, Huilai;
    • Ji, Jie;
    • Xu, Wei;
    • Jin, Jie;
    • Lv, Fangfang;
    • Feng, Ru;
    • Gao, Sujun;
    • Zhou, Daobin;
    • Tam, Constantine S.;
    • Simpson, David;
    • Wang, Michael;
    • Phillips, Tycel J.;
    • Opat, Stephen;
    • Fang, Cheng
    Publication type:
    Article
    17
    18

    First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs. ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

    Published in:
    Acta Haematologica Polonica, 2022, v. 53, n. A, p. 32
    By:
    • Jurczak, Wojciech;
    • Eichhorst, Barbara;
    • Brown, Jennifer J.;
    • Lamanna, Nicole;
    • O'Brien, Susan;
    • Tam, Constantine S.;
    • Lugui Qiu;
    • Kazmierczak, Maciej;
    • Zhou, Keshu;
    • Šimkovič, Martin;
    • Mayer, Jiri;
    • Gillespie-Twardy, Amanda;
    • Shadman, Mazyar;
    • Ferrajoli, Alessandra;
    • Ganly, Peter S.;
    • Weinkove, Robert;
    • Salmi, Tommi;
    • Wu, Kenneth;
    • Novotny, William;
    • Hillmen, Peter
    Publication type:
    Article
    19

    Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.

    Published in:
    Investigational New Drugs, 2023, v. 41, n. 4, p. 606, doi. 10.1007/s10637-023-01376-1
    By:
    • Song, Yuqin;
    • Zhou, Keshu;
    • Yang, Shenmiao;
    • Hu, Jianda;
    • Zou, Dehui;
    • Gao, Sujun;
    • Pan, Ling;
    • Wang, Tingyu;
    • Yang, Haiyan;
    • Zhang, Huilai;
    • Zhou, Daobin;
    • Ji, Jie;
    • Xu, Wei;
    • Feng, Ru;
    • Jin, Jie;
    • Lv, Fangfang;
    • Huang, Haiwen;
    • Fan, Xiaosi;
    • Xu, Sheng;
    • Zhu, Jun
    Publication type:
    Article
    20
    21

    Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 4, p. 571, doi. 10.1002/ajh.26826
    By:
    • Xu, Wei;
    • Zhou, Keshu;
    • Wang, Tingyu;
    • Yang, Shenmiao;
    • Liu, Lihong;
    • Hu, Yu;
    • Zhang, Wei;
    • Ding, Kaiyang;
    • Zhou, Jianfeng;
    • Gao, Sujun;
    • Xu, Bing;
    • Zhu, Zunmin;
    • Liu, Ting;
    • Zhang, Huilai;
    • Hu, Jianda;
    • Ji, Chunyan;
    • Wang, Shunqing;
    • Xia, Zhongjun;
    • Wang, Xin;
    • Li, Yan
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 3, p. 712, doi. 10.1080/10428194.2022.2164692
    By:
    • Xu, Wei;
    • Yang, Shenmiao;
    • Zhou, Keshu;
    • Pan, Ling;
    • Li, Zengjun;
    • Gao, Sujun;
    • Zhou, Daobin;
    • Hu, Jianda;
    • Feng, Ru;
    • Huang, Haiwen;
    • Wang, Tingyu;
    • Li, Dengju;
    • Ji, Meng;
    • Guo, Haiyi;
    • Zhao, Xia;
    • Wu, Binghao;
    • Yu, Yiling;
    • Wang, Yu;
    • Huang, Jane;
    • Novotny, William
    Publication type:
    Article
    32
    33
    34
    35
    36
    37

    Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.

    Published in:
    2021
    By:
    • Song, Yuqin;
    • Zhou, Hui;
    • Zhang, Huilai;
    • Liu, Wei;
    • Shuang, Yuerong;
    • Zhou, Keshu;
    • Lv, Fangfang;
    • Xu, Hao;
    • Zhou, Jianfeng;
    • Li, Wei;
    • Wang, Huaqing;
    • Zhang, Hongyu;
    • Huang, Haiwen;
    • Zhang, Qingyuan;
    • Xu, Wei;
    • Ge, Zheng;
    • Xiang, Ying;
    • Wang, Shuye;
    • Gao, Da;
    • Yang, Shun'e
    Publication type:
    journal article